EU/3/18/2111
Table of contents
About
On 14 December 2018, orphan designation (EU/3/18/2111) was granted by the European Commission to RHEACELL GmbH & Co. KG, Germany, for allogeneic ABCB5-positive limbal stem cells (also known as LSC2) for the treatment of limbal stem cell deficiency.
Key facts
Active substance |
Allogeneic ABCB5-positive limbal stem cells
|
Disease / condition |
Treatment of limbal stem cell deficiency
|
Date of first decision |
14/12/2018
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2111
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
RHEACELL GmbH & Co. KG
Im Neuenheimer Feld 517
69120 Heidelberg
Germany
Tel. +49 6221 718330
E-mail: office@rheacell.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.